Chemosensitizing and nephroprotective effect of resveratrol in cisplatin –treated animals

Cancer Cell International

Fatemah Kamel³  Lateef M Khan³  Mohamed F Elshal⁴  Wafaa S Ramadan²  Huda M Al-Kreathy³  Sameer E Al-Harthy³  Zoheir A Damanhouri³  Saud A Telity³  Abdel-Moneim M Osman¹ 

[1] Pharmacology unit, National Cancer Institute, Cairo University, Cairo 11796, Egypt;Anatomy Department, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia;Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia;Molecular Biology and Genetic engineering and Biotechnology Department, Minoufia Universitym Minoufia, Minoufia, Egypt

关键词: Nephroprotection;    Resveratrol;    Cisplatin;   

Others  :  1138650
DOI  :  10.1186/s12935-014-0152-2

 received in 2014-10-16, accepted in 2014-12-22,  发布年份 2015

【 摘 要 】

Background

Cisplatin (CIS) is one of the most effective anticancer drug used in the treatment of several solid tumors .Its use is limited by its nephrotoxicity. The present study was designed to assess the role of a natural product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma) to the action of CIS and the possible protective effect against CIS-induced nephrotoxicity in rats.

Methods

The percent survival of female tumor bearing mice was used for determination the cytotoxic activity of CIS in the presence or the absence of RSVL. Uptake and cell cycle effect, serum creatinine (CREA), blood urea nitrogen (BUN), Reduced Glutathione (GSH) and histopatholgical examination of kidney tissues after CIS and/or RSVL therapy were also investigated.

Results

RSVL increased the intracellular level of CIS in EAC cells and there was a strong correlation between the high cellular level of CIS and its cytotoxicity. CIS at a dose level of 5 mg/kg increased the mean survival time of female tumor bearing mice to 25 days compared with 17 days for tumor-bearing control mice. Administration of RSVL at a dose level of 25 mg/kg simultaneously with CIS increased the mean survival time to 48 days with 60% survival of the tumor-bearing animals. Cell cycle analysis of tumor cells showed that CIS treatment decreases the proliferation index of tumor cells while in presence of RSVL there was more significant inhibitions. Also, CIS treatment caused increase in level of creatinine and blood urea with significant decrease in the GSH level. While, in the presence of RSVL, level of creatinine and blood urea restored to control level.

Conclusion

This study suggests that RSVL could increase the cytotoxic activity of CIS and protect against its nephrotoxicity.

【 授权许可】

   
2015 Osman et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Lebwohl D, Canetta R: Clinical development of platinum complexesincancertherapy: an historical perspective and an update. Eur J Cancer 1998, 34(10):1522-34.
• [2]Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R: A novel site of erythropoietin production: oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994, 269:19488-93.
• [3]Jin-Gang Z, Lindup WE: Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 1993, 45(11):2215-22.
• [4]Khynriam D, Prasad SB: Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biology Toxicol 2002, 18(6):349-58.
• [5]Osman AM, Bayoumi HM, Al-Harthi SE, Damanhouri ZA, Elshal MF: Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int 2012, 12(1):47. BioMed Central Full Text
• [6]Vitrac X, Bornet A, Vanderlinde R, Valls J, Richard T, Delaunay JC, Teissédre PL: Determination of stilbenes (Δ-Viniferin, Trans-Astringin, Trans-Piceid, Cis-And Trans-Resveratrol, Ε-Viniferin) in Brazilian wines. J Agric Food Chem 2005, 53(14):5664-9.
• [7]Donenko FV, Efferth T, Mattern J, Moroz LV, Volm M: Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil. Chemotherapy 1991, 37(1):57-61.
• [8]Smets LA, Bout B, Broiwer M: Tulp A: cytotoxic effect of dexamethasone restricted to noncycling early G1 phase cells of L1210 leukemia. J Cell Physiol 1983, 116(3):397-403.
• [9]Beutler F, Duron O, Kelly MB: Improved method of estimation of blood glutathione. J Lab Clin Med 1963, 61(5):882.
• [10]Galea AM, Murray V: The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta Gene Struct Expr 2002, 1579(2):142-52.
• [11]Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol O: Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 2003, 47(2):149-56.
• [12]Behling EB, Sendao MC, Francescato HD, Antunes LM, Costa RS, De Lourdes Pbianchi M: Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol Rep 2006, 58(4):526.
• [13]Osman AMM, Al-Harthi SE, Alarabi OM, Elshal MF, Ramadan WS, Alaama MN, Osman OH: Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int 2013, 13(1):1-8. BioMed Central Full Text
• [14]Rezk YA, Balulad SS, Keller RS, Bennett JA: Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 2006, 194:23-6.
• [15]Nessa MU, Beale P, Chan C, Yu JQ, Huq F: Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res 2012, 32:53-9.
• [16]Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI, El-Shemy HA: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 2011, 44:591-601.
• [17]Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011, 1215:150-60.
• [18]Yang SY, Tsai SY, Hou YC, Chao PDL: Inductive modulation on p-gp and cytochrome 3a by resveratrol, a constituent of grapes. Food Chem 2012, 133(3):683-8.
• [19]Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993, 85(8):632-9.
• [20]Herzog CE, Tsokos M, Bates SE, Fojo AT: Increased Mdr-1/P-gp expression after treatment of human colon carcinoma cells with P-gp antagonists. J Biol Chem 1993, 268(4):2946-52.
• [21]Walworth NC: Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol 2000, 12(6):697-704.
• [22]Zhou BBS, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000, 408(6811):433-9.
• [23]Wolfgang GH, Dominick MA, Walsh K, Hoeschele JD, Pegg DG: Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male wistar rats. Toxicol Sci 1994, 22(1):73-9.
• [24]Matsushima H, Yonemura K, Ohishi K, Hishida A: The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998, 131(6):518-26.
• [25]Levi J, Jacobs C, Kalman SM, Mctigue M, Weiner MW: Mechanism of cis-platinum nephrotoxicity: i. effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 1980, 213(3):545-50.
• [26]Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E, Kroemer G: Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle 2012, 11(18):3472.
• [27]Wang J, He D, Zhang Q, Han Y, Jin S, Qi F: Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009, 24:675-80.